Trastuzumab

證據等級: L5

預測適應症: 10 個

Trastuzumab: From HER2-Positive Breast Cancer to Normal Breast-Like Subtype of Breast Carcinoma

One-Sentence Summary

Trastuzumab (Herceptin) is a monoclonal antibody long established for HER2-positive breast cancer (and HER2-positive gastric cancer). The TxGNN model predicts it may also be relevant to normal breast-like subtype of breast carcinoma, a PAM50 molecular subtype, but this is currently supported by only 12 clinical trials (mostly on HER2+ breast cancer broadly, not this subtype specifically) and 1 publication (a morphology/pathology study, not a treatment trial).

Quick Overview

Item	Content
Original Indication	HER2-positive breast cancer (well-established use; Evidence Pack does not contain Taiwan/US regulatory license text — see Data Gap below)
Predicted New Indication	Normal breast-like subtype of breast carcinoma
TxGNN Prediction Score	99.90%
Evidence Level	L2
US Market Status	未上市 (Not marketed, per Evidence Pack)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack (flagged as a High-severity data gap, DG002). Based on general public knowledge, trastuzumab is a humanized monoclonal antibody that binds the extracellular domain of HER2, blocking HER2-driven proliferation and mediating antibody-dependent cellular cytotoxicity (ADCC) — its efficacy in HER2-overexpressing breast (and gastric) cancer is well established.

The predicted new indication, “normal breast-like subtype of breast carcinoma,” refers to one of the five PAM50 intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched, Basal-like, Normal-like). This subtype is typically characterized by low HER2 expression, which weakens the direct mechanistic rationale for trastuzumab, since the drug’s activity depends on HER2 overexpression.

The AI’s own rationale for this candidate is explicit about this limitation: “normal breast-like” is a PAM50 intrinsic subtype typically associated with low HER2 expression, which has a weak mechanistic link to trastuzumab’s HER2-overexpression target; the listed trials largely study HER2+ breast cancer populations broadly rather than this subtype specifically, so the high TxGNN score likely reflects trastuzumab’s broad association with breast cancer rather than a subtype-specific mechanism. This should be read as a caution against over-interpreting the score.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05900206	Phase 2	Recruiting	370	ARIADNE: T-DXd vs. standard preoperative therapy in HER2+ breast cancer, using biology-driven (subtype) treatment selection
NCT03168880	Phase 3	Active, not recruiting	720	Neoadjuvant weekly paclitaxel ± carboplatin in triple-negative breast cancer; not specific to trastuzumab or normal-like subtype
NCT01670877	Phase 2	Completed	56	Neratinib ± fulvestrant in HER2 non-amplified but HER2-mutant breast cancer — mechanistically opposite to trastuzumab’s target population
NCT05659056	Phase 2	Recruiting	65	Pyrotinib + trastuzumab + Abraxane neoadjuvant therapy in HER2-enriched early/locally advanced breast cancer, using PAM50/BluePrint subtyping
NCT04329065	Phase 2	Recruiting	25	WOKVAC vaccine + neoadjuvant chemotherapy + HER2-targeted monoclonal antibody therapy
NCT05582499	Phase 2	Recruiting	716	FASCINATE-N: precision neoadjuvant therapy platform stratified by clinical/molecular subtype
NCT06585969	Phase 3	Withdrawn	0	T-DXd vs. CDK4/6 inhibitors in non-Luminal A, ER+/HER2-low metastatic breast cancer (trial withdrawn)
NCT01796197	Phase 2	Completed	23	Paclitaxel + trastuzumab + pertuzumab as preoperative therapy for inflammatory breast cancer
NCT06328387	Phase 1/2	Unknown	120	Hydroxychloroquine + ADC vs. ADC alone in advanced breast cancer
NCT04759248	Phase 2	Active, not recruiting	55	ATREZZO: atezolizumab + trastuzumab + vinorelbine in ER-negative or PAM50 non-luminal HER2+ advanced/metastatic breast cancer

None of the above trials specifically enroll or report outcomes for the “normal breast-like” PAM50 subtype as a defined study population.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19466513	2009	Pathology/Morphology study	Breast Cancer (Tokyo, Japan)	Describes morphological/cytopathological characteristics of PAM50 subtypes (including normal breast-like); does not report treatment outcomes with trastuzumab

Cytotoxicity

Trastuzumab is an antineoplastic (HER2-targeted monoclonal antibody), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (anti-HER2 monoclonal antibody)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions (as an anti-HER2 agent, cardiac function/LVEF monitoring is a known clinical consideration for this drug class)
Handling Protection	Please refer to the package insert warnings and precautions

No specific toxicity data was provided in this Evidence Pack (safety fields were flagged as Data Gaps).

Safety Considerations

Please refer to the package insert for safety information. In addition, note that TFDA-specific warnings/contraindications for this drug are flagged as a Blocking data gap (DG001) — this must be resolved before any safety (S1) assessment can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic link between trastuzumab and the “normal breast-like” PAM50 subtype is weak, since this subtype typically has low HER2 expression. Evidence is limited to L2 (no trial directly tests this subtype) and the decision stage is S1 (Research Question), with the AI’s own rationale flagging that the high TxGNN score likely reflects trastuzumab’s general breast-cancer association rather than a subtype-specific mechanism.

To proceed, the following is needed:

TFDA package insert warnings/contraindications (Blocking gap, DG001) before any safety review can begin
Confirmed mechanism of action data from DrugBank (High-priority gap, DG002)
A clinical trial or biomarker study specifically stratifying HER2/PAM50-normal-like patients and reporting trastuzumab outcomes in that subgroup
Taiwan/US regulatory licensing data currently missing from this Evidence Pack

Note: Two other predicted indications in this candidate set — progesterone-receptor positive breast cancer and progesterone-receptor negative breast cancer — carry substantially stronger evidence (L1, multiple completed Phase 3 RCTs, decision stage S3, “Proceed with Guardrails”) and largely represent confirmation of trastuzumab’s existing HER2+ breast cancer indication rather than a novel repurposing hypothesis. These may warrant separate, higher-priority review.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.